Protocol No
BEIGENE-BGB-11417-103
Phase
I/II
Summary
This project is being done to look at the safety and tolerability of an investigational anticancer drug, currently known as BGB-11417, when given in combination with azacitidine.
Description
A Phase 1b/2 Study of BGB-11417 in Patients with Myeloid Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov